Free Trial
Lucas Ward

Lucas Ward Analyst Performance

Senior Research Analyst at Ascendiant Capital Markets

Lucas Ward is a stock analyst at Ascendiant Capital Markets focused in the medical sector, covering 4 publicly traded companies. Over the past year, Lucas Ward has issued 8 stock ratings, including and buy recommendations. While full access to Lucas Ward's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Lucas Ward's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
8 Last 0 Years
Buy Recommendations
100.00% 8 Buy Ratings
Companies Covered
4 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy100.0%8 ratings
Hold0.0%0 ratings
Sell0.0%0 ratings

the majority (100.0%) have been Buy recommendations.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
4 companies

Lucas Ward, an analyst at Ascendiant Capital Markets, currently covers 4 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
3 companies
75.0%
Industrials
1 company
25.0%

Lucas Ward of Ascendiant Capital Markets specializes in stock coverage within the Medical sector, with additional focus on Industrials companies.

Coverage Industries

IndustryPercentage
MED - DRUGS
2 companies
50.0%
MEDICAL INFO SYS
1 company
25.0%
POLLUTION CNTRL
1 company
25.0%

About Lucas Ward

Mr. Ward is a Senior Research Analyst for Ascendiant Capital Markets LLC. Mr. Ward has over twenty-five years of experience as an equity research analyst, strategic advisor, and entrepreneur. Prior to Ascendiant, Mr. Ward was an equity research analyst at JP Morgan Chase, Goldman Sachs Asia, and Hambrecht & Quist. During that time, he served as a trusted resource for institutional investors regarding the technology industry, equity valuations, and investment opportunities. Mr. Ward made regular appearances in investment media, and participated in roadshows to educate and engage with institutional investors in the US, Europe, and Asia. As an entrepreneur, Mr. Ward created a luminous original music franchise with over 4 million followers globally reached through Facebook, Instagram, YouTube, Twitter, Spotify, SoundCloud, press, television, and radio. Mr. Ward earned a Bachelor of Arts degree in Asian Languages and Civilizations from Amherst College and he attended Peking University where he studied Chinese Language and History. He has full written and verbal fluency in Mandarin Chinese and Italian, and has conversational fluency in Cantonese, Japanese, Spanish, and French. Mr. Ward maintains FINRA Series 7, 63, 66, and 87 securities registrations.
Follow on LinkedIn

Lucas Ward's Ratings History at Ascendiant Capital Markets

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
HeartSciences Inc. stock logo
HSCS
HeartSciences
10/1/2025Lower Price Target$3.48$9.00Buy
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
9/9/2025Boost Price Target$3.83$6.50Buy
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
9/3/2025Lower Price Target$1.42$3.00Buy
LiqTech International, Inc. stock logo
LIQT
LiqTech International
6/16/2025Boost Price Target$1.51$3.60Buy
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
6/2/2025Boost Price Target$2.59$7.00Buy
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
4/15/2025Lower Price Target$2.25$6.20Buy
LiqTech International, Inc. stock logo
LIQT
LiqTech International
4/7/2025Reiterated Rating$1.56$3.40Buy
HeartSciences Inc. stock logo
HSCS
HeartSciences
3/18/2025Lower Price Target$3.05$14.00Buy